Art. 46 Directive (EU) 2001/83

In forcesince 21 Jul 2011cited 7×

The holder of a manufacturing authorization shall at least be obliged:

(a)

to have at his disposal the services of staff who comply with the legal requirements existing in the Member State concerned both as regards manufacture and controls;

(b)

to dispose of the authorized medicinal products only in accordance with the legislation of the Member States concerned;

(c)

to give prior notice to the competent authority of any changes he may wish to make to any of the particulars supplied pursuant to Article 41; the competent authority shall, in any event, be immediately informed if the qualified person referred to in Article 48 is replaced unexpectedly;

(d)

to allow the agents of the competent authority of the Member State concerned access to his premises at any time;

(e)

to enable the qualified person referred to in Article 48 to carry out his duties, for example by placing at his disposal all the necessary facilities;

(f)

to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use only active substances, which have been manufactured in accordance with good manufacturing practice for active substances and distributed in accordance with good distribution practices for active substances. To this end, the holder of the manufacturing authorisation shall verify compliance by the manufacturer and distributors of active substances with good manufacturing practice and good distribution practices by conducting audits at the manufacturing and distribution sites of the manufacturer and distributors of active substances. The holder of the manufacturing authorisation shall verify such compliance either by himself or, without prejudice to his responsibility as provided for in this Directive, through an entity acting on his behalf under a contract.

The holder of the manufacturing authorisation shall ensure that the excipients are suitable for use in medicinal products by ascertaining what the appropriate good manufacturing practice is. This shall be ascertained on the basis of a formalised risk assessment in accordance with the applicable guidelines referred to in the fifth paragraph of Article 47. Such risk assessment shall take into account requirements under other appropriate quality systems as well as the source and intended use of the excipients and previous instances of quality defects. The holder of the manufacturing authorisation shall ensure that the appropriate good manufacturing practice so ascertained, is applied. The holder of the manufacturing authorisation shall document the measures taken under this paragraph;

(g)

to inform the competent authority and the marketing authorisation holder immediately if he obtains information that medicinal products which come under the scope of his manufacturing authorisation are, or are suspected of being, falsified irrespective of whether those medicinal products were distributed within the legal supply chain or by illegal means, including illegal sale by means of information society services;

(h)

to verify that the manufacturers, importers or distributors from whom he obtains active substances are registered with the competent authority of the Member State in which they are established;

(i)

to verify the authenticity and quality of the active substances and the excipients.

  • Arrêt du Tribunal (septième chambre) du 7 mars 2013. Acino AG (anciennement Acino Pharma GmbH) contre Commission européenne.Decision

    … und Leitlinien guter Herstellungspraktiken für Arzneimittel (im Folgenden: gute Herstellungspraxis), auf die in Art. 46 Buchst. f der Richtlinie 2001/83/EG des Europäischen Parlaments und des Rates vom 6. November 2001 zur Schaffung …

    7 Mar 2013 · 62010TJ0539

  • Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…61Law

    … Членове от 42 до 45 и член 46, буква д) от Директива 2001/83/ЕО се прилагат, mutatis mutandis, за разрешението, посочено в параграф 1. 5. Параграф 1 не …

  • Judgment of the Court (Sixth Chamber), 10 April 2014. Acino AG v European Commission.Decision

    Under Article 46 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), as amended by Directive 2004/27/EC of the …

    10 Apr 2014 · 62013CJ0269

  • Opinion of Advocate General Sharpston delivered on 31 January 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision

    Article 46 specifies the obligations imposed on the holders of manufacturing authorisations. They essentially concern the manufacturing process as such; and include a duty to comply with the principles of good manufacturing practice for …

    31 Jan 2013 · 62011CC0535

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision

    Articles 41 to 53 of Directive 2001/83 specify the conditions that those national authorisation regimes must satisfy. In particular, the manufacturer in question must make an application and supply a range of information in support of it. …

    25 Jul 2018 · 62017CC0029

  • BVerwG, Urteil vom 3. September 2020 - 3 C 10/18Decision

    … hierzu auch Art. 46 der Richtlinie 2001/83/EG des Europäischen Parlaments und des Rates vom 6. November 2001 zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel <ABl. L 311 S. 67>, zuletzt geändert durch die Verordnung <EU> …

    3 Sep 2020 · WBRE202000854

  • The Medicines (Standard Provisions for Licences and Certificates) Amendment Regulations…Law

    … the standard provisions of licences granted to manufacturers of medicinal products, including the requirement in Article 46 of Directive 2001/83/EC, relating to medicinal products for human use, to comply with “good manufacturing …